1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good Prognosis Diffuse Large B Cell Lymphoma (DLBCL) Results of the 6 Year Follow up of the Mint Study of the Mabthera International Trial (Mint) Group
(
- Contribution to journal › Published meeting abstract
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
CNS Disease In Younger Patients (
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.1082-1082(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2007
-
Mark
Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
- 2003
-
Mark
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
(
- Contribution to journal › Article
-
Mark
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
(
- Contribution to journal › Article